Ledipasvir and Sofosbuvir for Hepatitis C Genotype 4: A Proof of Concept Phase 2a Cohort Study

BACKGROUND: Chronic hepatitis C (HCV) genotype 4 (GT-4) represents up to 13% of HCV infections globally, concentrated in resource limited countries in the Middle East and Africa. In patients with HCV GT-1, the combination of ledipasvir and sofosbuvir has shown high cure rates with excellent tolerabi...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Lancet Infect Dis
Autors principals: Kohli, Anita, Kapoor, Rama, Sims, Zayani, Nelson, Amy, Sidharthan, Sreetha, Lam, Brian, Silk, Rachel, Kotb, Colleen, Gross, Chloe, Teferi, Gebeyehu, Sugarman, Kate, Pang, Phillip S., Osinusi, Anu, Polis, Michael A., Rustgi, Vinod, Masur, Henry, Kottilil, Shyam
Format: Artigo
Idioma:Inglês
Publicat: 2015
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4561573/
https://ncbi.nlm.nih.gov/pubmed/26187031
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S1473-3099(15)00157-7
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars